國立虎尾科技大學 |

Novel immunotherapeutic approaches to the treatment of cancer = drug development and clinical application /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Novel immunotherapeutic approaches to the treatment of cancer/ edited by Paul D. Rennert.
其他題名:	drug development and clinical application /
其他作者:	Rennert, Paul D.
出版者:	Cham :Springer International Publishing : : 2016.,
面頁冊數:	xi, 276 p. :ill., digital ; : 24 cm.;
Contained By:	Springer eBooks
標題:	Cancer - Immunotherapy. -
電子資源:	http://dx.doi.org/10.1007/978-3-319-29827-6
ISBN:	9783319298276

Novel immunotherapeutic approaches to the treatment of cancer = drug development and clinical application /
Novel immunotherapeutic approaches to the treatment of cancerdrug development and clinical application /[electronic resource] :edited by Paul D. Rennert. - Cham :Springer International Publishing :2016. - xi, 276 p. :ill., digital ;24 cm.

Introduction -- Enhancing the efficacy of checkpoint blockade through combination therapies -- Novel Immunomodulatory Targets in the Immunoglobulin-Superfamily -- Parallel Costimulation of Effector and Regulatory T Cells by OX40, GITR, TNFRSF25, CD27 and CD137 -- NK Cell Responses in Immunotherapy -- Reversing T cell dysfunction for tumor immunotherapy -- Immunomodulation within a single tumor site to induce systemic anti-tumor immunity -- Novel Targets and Their Assessment for Cancer Treatment -- The New Frontier of Antibody Drug Conjugates -- Cellular Therapies -- Targeting the Physicochemical, Cellular, and Immunosuppressive Properties of the Tumor Microenvironment by Depletion of Hyaluronan to Treat Cancer.

Cancer care is undergoing a radical transformation as novel technologies are directed toward new treatments and personalized medicine. The most dramatic advances in the treatment of cancer have come from therapeutics that augment the immune response to tumors. The immune checkpoint inhibitors are the best-known and most highly advanced examples of Immune Therapeutics targeting tumor cells and include approved antibody drugs directed at the cell surface proteins CTLA4 and PD-1. These are now considered foundational treatments for several solid tumor indications, and that list of indications is growing quickly. More broadly, antibodies have become workhorse molecules across the entire immunotherapy landscape. Antibodies to novel targets modulate the activity of diverse immune cell regulatory proteins. Engineered antibodies can induce tumor cell death or expose tumor cells to poisonous toxins (ADCC and ADC, respectively) Bi-specific antibodies can engage multiple tumor targets simultaneously, or can redirect lymphocytes to attack tumor cells. The antigen-binding domains within antibodies can be spliced onto cell stimulatory domains and transduced into T cells or NK cells, creating remarkable tumor-specific cellular therapeutics (CAR-T, CAR-NK) Beyond antibody-based therapies there are highly diverse and differentiated technology tool kits being applied to immunotherapy. Small molecule drugs are being developed to attack the tumor microenvironment, novel tumor vaccine approaches are showing great promise, patient lymphocytes are being isolated, expanded and reintroduced to patients, gene-editing techniques are becoming widely deployed, and a vast number of new tumor targets, and mutated tumor proteins (neoantigens), are being discovered. The past decade has seen unprecedented success in the treatment of diverse cancers. The authors of this volume have been asked to not only review progress to date, but importantly, to look ahead, and anticipate the evolution of cancer treatment across diverse Immune Therapeutic approaches. Our hypothesis is that the advances we are seeing across the immunotherapy landscape will further evolve and synergize, leading us finally to outright cures for many cancers.

ISBN: 9783319298276

Standard No.: 10.1007/978-3-319-29827-6doiSubjects--Topical Terms:

645557
Cancer
--Immunotherapy.

LC Class. No.: RC271.I45

Dewey Class. No.: 616.99406

Novel immunotherapeutic approaches to the treatment of cancer = drug development and clinical application /
LDR:03952nam a2200313 a 4500 001 864025
003 DE-He213
005 20161019115206.0
006 m d
007 cr nn 008maaau
008 170720s2016 gw s 0 eng d
020 $a 9783319298276 $q (electronic bk.)
020 $a 9783319298252 $q (paper)
024 7 $a 10.1007/978-3-319-29827-6 $2 doi
035 $a 978-3-319-29827-6
040 $a GP $c GP
041 0 $a eng
050 4 $a RC271.I45
072 7 $a MJCM $2 bicssc
072 7 $a MED044000 $2 bisacsh
082 0 4 $a 616.99406 $2 23
090 $a RC271.I45 $b N937 2016
245 0 0 $a Novel immunotherapeutic approaches to the treatment of cancer $h [electronic resource] : $b drug development and clinical application / $c edited by Paul D. Rennert.
260 $a Cham : $c 2016. $b Springer International Publishing : $b Imprint: Springer,
300 $a xi, 276 p. : $b ill., digital ; $c 24 cm.
505 0 $a Introduction -- Enhancing the efficacy of checkpoint blockade through combination therapies -- Novel Immunomodulatory Targets in the Immunoglobulin-Superfamily -- Parallel Costimulation of Effector and Regulatory T Cells by OX40, GITR, TNFRSF25, CD27 and CD137 -- NK Cell Responses in Immunotherapy -- Reversing T cell dysfunction for tumor immunotherapy -- Immunomodulation within a single tumor site to induce systemic anti-tumor immunity -- Novel Targets and Their Assessment for Cancer Treatment -- The New Frontier of Antibody Drug Conjugates -- Cellular Therapies -- Targeting the Physicochemical, Cellular, and Immunosuppressive Properties of the Tumor Microenvironment by Depletion of Hyaluronan to Treat Cancer.
520 $a Cancer care is undergoing a radical transformation as novel technologies are directed toward new treatments and personalized medicine. The most dramatic advances in the treatment of cancer have come from therapeutics that augment the immune response to tumors. The immune checkpoint inhibitors are the best-known and most highly advanced examples of Immune Therapeutics targeting tumor cells and include approved antibody drugs directed at the cell surface proteins CTLA4 and PD-1. These are now considered foundational treatments for several solid tumor indications, and that list of indications is growing quickly. More broadly, antibodies have become workhorse molecules across the entire immunotherapy landscape. Antibodies to novel targets modulate the activity of diverse immune cell regulatory proteins. Engineered antibodies can induce tumor cell death or expose tumor cells to poisonous toxins (ADCC and ADC, respectively) Bi-specific antibodies can engage multiple tumor targets simultaneously, or can redirect lymphocytes to attack tumor cells. The antigen-binding domains within antibodies can be spliced onto cell stimulatory domains and transduced into T cells or NK cells, creating remarkable tumor-specific cellular therapeutics (CAR-T, CAR-NK) Beyond antibody-based therapies there are highly diverse and differentiated technology tool kits being applied to immunotherapy. Small molecule drugs are being developed to attack the tumor microenvironment, novel tumor vaccine approaches are showing great promise, patient lymphocytes are being isolated, expanded and reintroduced to patients, gene-editing techniques are becoming widely deployed, and a vast number of new tumor targets, and mutated tumor proteins (neoantigens), are being discovered. The past decade has seen unprecedented success in the treatment of diverse cancers. The authors of this volume have been asked to not only review progress to date, but importantly, to look ahead, and anticipate the evolution of cancer treatment across diverse Immune Therapeutic approaches. Our hypothesis is that the advances we are seeing across the immunotherapy landscape will further evolve and synergize, leading us finally to outright cures for many cancers.
650 0 $a Cancer $x Immunotherapy. $3 645557
650 1 4 $a Biomedicine. $3 593880
650 2 4 $a Immunology. $3 592892
650 2 4 $a Cancer Research. $3 668358
650 2 4 $a Oncology. $3 593951
650 2 4 $a Pharmacology/Toxicology. $3 593882
700 1 $a Rennert, Paul D. $3 1108601
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer eBooks
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-29827-6
950 $a Biomedical and Life Sciences (Springer-11642)